ChemicalBook > CAS DataBase List > Veliparib

Veliparib

Abstract Biological activity In vitro In vivo Features References

Veliparib

CAS No.912444-00-9
Chemical Name:Veliparib
CBNumber:CB22489643
Molecular Formula:C13H16N4O
Formula Weight:244.29
MOL File:912444-00-9.mol

Veliparib Property

Boiling point 579.0±40.0 °C(Predicted)
Density 1.274
storage temp. Store at -20°C
solubility insoluble in H2O; ≥10.6 mg/mL in EtOH with ultrasonic; ≥6.11 mg/mL in DMSO
form solid
pka 9.22±0.30(Predicted)
color White to off-white
CAS DataBase Reference 912444-00-9
NCI Dictionary of Cancer Terms veliparib
FDA UNII 01O4K0631N
NCI Drug Dictionary veliparib
ATC code L01XK05

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal wordWarning
Hazard statements H341-H373-H361-H302
Precautionary statements P201-P202-P281-P308+P313-P405-P501-P260-P314-P501-P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501

Veliparib Chemical Properties,Usage,Production

Abstract Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Veliparib (ABT-888) is being investigated to treat squamous and non-squamous non-small cell lung cancer, BRCA breast cancer, triple negative breast cancer and ovarian cancer.
Biological activity Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
In vitro Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor，which inhibits PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays，respectively.ABT-888 reduces clonogenic survival and inhibits DNA repair in H460 cells. ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells.
In vivo ABT-888 inhibits PARP in B16F10 and 9L xenograft models, thus enhancing the anticancer activity of temozolomide. The Combined with other cytotoxic agents, ABT-888 shows strong antitumor effect in MX-1 xenograft model. ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg according to the the size of tumors in A375 and Colo829 xenograft models.
Features ABT-888 enhances the effectiveness of common cancer treatments, such as radiation therapy and alkylating agents.
References https://www.abbvie.com/our-science/pipeline/veliparib.html
https://en.wikipedia.org/wiki/Veliparib
Chemical Properties Off-White Solid
Uses ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ) and develop a biological marker for PARP inhibition was evaluated in vivo.
Definition ChEBI: A benzimidazole substituted with a carbamoyl group at C-4 and a (2R)-2-methylpyrrolidin-2-yl moiety at C-2. It is a potent, orally bioavailable PARP inhibitor.
Biological Activity abt-888, also named as veliparib, is poly (adp-ribose) polymerase (parp) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents. parp is involved in dna repair and elevated parp levels can result in resistance to cytotoxic chemotherapy and radiation. so, parp inhibitors hold promise as chemotherapy and radiation sensitizers. abt-888 is also active on microsatellite instability (msi) cell lines harboring mutations in both mre11 and rad50 genes compared to microsatellite stable (mss) cell lines (wild-type for both genes).shivaani kummar, robert kinders, martin e. gutierrez, larry rubinstein, ralph e. parchment, lawrence r. phillips, jiuping ji, anne monks, jennifer a. low, alice chen, anthony j. murgo, jerry collins, seth m. steinberg, helen eliopoulos, vincent l. giranda, gary gordon, lee helman, robert wiltrout, joseph e. tomaszewski and james h. doroshow. phase 0
in vivo
Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier in syngeneic and xenograft tumor models^[1]. In MDA-MB-231 xenograft tumor models, combination treatment (AG014699/PF-02341066 and Veliparib (ABT-888)/Foretinib) substantially reduced tumor growth compared to either inhibitor alone^[2].
IC 50 PARP-2: 2.9 nM (Ki); PARP-1: 5.2 nM (Ki); Autophagy